RE: Q&A out19 Jul 2021 10:34
I know not LFT related - Q22 is interesting
Q22: AVA6000 - Are there significant amounts of FAP associated with Circulating Tumour Cells capable of causing the release of the chemotherapy away from the tumour?
Circulating tumour cells are very rare; there is approximately one circulating tumour cell for every million blood cells. The number of FAP positive circulating tumour cells is in the region of 26–49 per ml of blood. It is therefore unlikely that FAP associated with circulating tumour cells contribute significantly to cleavage of AVA6000 in the blood.
Relative to expression in most normal tissues, FAP is overexpressed on the cell membrane of stromal fibroblasts in many epithelial tumours and in soft tissue sarcomas. Thus, the preCISION platform provides a means to target the activation of a chemotherapy, such as doxorubicin in the case of AVA6000, to the tumour bed while reducing exposure of normal tissues.
(https://www.nature.com/articles/s41698-017-0028-8#Sec2)
as well as:
Q24: Will AVA6000 be quicker to market compared to novel cancer treatments, considering doxorubicin is already approved?
Since the active drug is an established, approved chemotherapy the regulatory pathway to approval may be shorter.